Director’s Bold Move: A Significant Investment in Tenax Therapeutics!

Tip Ranks
2025.11.20 02:15
portai
I'm PortAI, I can summarize articles.

Director June Sherie Almenoff invested in Tenax Therapeutics by purchasing 1,993 shares for $14,933, signaling confidence in the company. Despite a Q3 net loss of $15.8 million due to increased R&D expenses, Tenax maintains a strong cash position of $99.4 million. The company is advancing Phase 3 trials and expects a new patent grant in Europe. However, Spark's AI Analyst rates TENX as "Underperform" due to financial challenges and reliance on equity financing.

New insider activity at Tenax Therapeutics ( (TENX) ) has taken place on November 19, 2025.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Director June Sherie Almenoff has made a notable investment in Tenax Therapeutics by purchasing 1,993 shares, valued at $14,933. This move reflects confidence in the company’s potential and could signal positive prospects for the future.

Recent Updates on TENX stock

In the last 24 hours, Tenax Therapeutics has experienced notable developments impacting its stock performance. The company reported its Q3 earnings, revealing a net loss of $15.8 million, primarily due to a significant increase in research and development expenses, which rose by 232% to $10.3 million. This increase is attributed to ongoing clinical trials for levosimendan and imatinib, aimed at treating pulmonary hypertension. Despite the losses, Tenax maintains a strong cash position of $99.4 million, supporting its operations through 2027. The company is advancing its Phase 3 clinical trials, with plans to enroll 230 patients in the ongoing LEVEL study and initiate the global LEVEL-2 study. Additionally, Tenax announced the European Patent Office’s intention to grant a patent for levosimendan in PH-HFpEF, which could enhance its market potential. These developments, along with an optimistic buy rating driven by a strong patent portfolio, have influenced investor sentiment and may impact future stock performance.

Spark’s Take on TENX Stock

According to Spark, TipRanks’ AI Analyst, TENX is a Underperform.

Tenax Therapeutics’ overall score reflects substantial financial challenges due to an absence of revenue and consistent losses, heavily reliant on equity financing. Technical indicators suggest neutral momentum, but poor financial performance and valuation overshadow any potential stability.

To see Spark’s full report on TENX stock, click here.

More about Tenax Therapeutics

YTD Price Performance: 17.33%

Average Trading Volume: 84,104

Technical Sentiment Signal: Sell

Current Market Cap: $45.89M

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer